Genetic Testing Market Size & Share 2026-2035

Genetic Testing Market Size

The genetic testing market was valued at USD 23.2 billion in 2025, is projected to reach USD 26.41 billion in 2026, and is expected to grow at a 12.3% CAGR (2026–2035) to attain USD 74.16 billion by 2035. The market encompasses testing products, laboratory services, and informatics used to analyze DNA, RNA, chromosomes, and related biomarkers across clinical, consumer, and institutional settings.

The market is shifting from specialist-ordered, single-gene testing toward panel-based workflows that combine assay performance, informatics, and clinical interpretation. Oncology companion diagnostics, noninvasive prenatal screening, hereditary disease assessment, and direct-to-consumer offerings create distinct demand channels, reducing reliance on a single testing modality or therapeutic category.

Report Coverage & Key Takeaways

This report assesses global genetic testing revenue across products and services, test types, applications, techniques, and end-use settings. It covers the 2022–2035 period, with 2025 as the base year, and examines five major regions and their constituent markets. Key themes include oncology-led testing demand, the growing commercial importance of interpretation software, regional differences in reimbursement and laboratory capacity, and moderate market concentration.

Genetic Testing Market Trends, Growth Drivers & GMI Forecast Outlook

Clinical adoption is becoming more dependent on whether laboratories can operationalize high-complexity assays at scale and whether payers recognize their value. The strongest outlook is tied to repeat-use oncology and longitudinal care applications, while coverage fragmentation and specialist shortages remain material conversion constraints.

Key Drivers

*Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.*

Clinical NGS insourcing changes the economics of genetic testing beyond instrument placement. Laboratories that internalize sequencing gain greater control over turnaround time, menu design, and integration with pathology and oncology workflows. This supports recurring demand for reagents and workflow software, while also raising the importance of service capabilities that help laboratories validate, interpret, and report increasingly complex panels ^{[1]L.E.K. Consulting. “Clinical NGS Testing Trends and Sample-to-Answer Platform Adoption.” lek.com}.

Testing maturity in established oncology indications is redirecting growth toward repeated and broader testing events rather than reducing the clinical opportunity. Liquid biopsy, molecular residual disease surveillance, and earlier detection models extend genomics across the treatment continuum, creating demand for assays that can support therapy selection, monitoring, and recurrence assessment in the same patient pathway ^{[2]IQVIA Institute for Human Data Science. “Advancing Precision Oncology.” iqvia.com}.

AI-assisted interpretation is particularly consequential for laboratories outside major academic centers. Automation can reduce the operational friction associated with variant classification and report generation, but its commercial impact depends on local computing capacity, clinical validation standards, and confidence among ordering physicians in the resulting interpretation.

Key Restraints

*Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.*

Coverage friction separates clinical eligibility from completed testing. Even where professional guidelines support testing, prior authorization requirements and uncertain benefit design can delay or prevent order fulfillment. This affects hereditary, rare disease, and preventive use cases particularly acutely because their value proposition may be recognized clinically before reimbursement policies are harmonized ^{[3]UCLA Health. “Patients Face Insurance Hurdles for Genetic Testing, Study Says.” uclahealth.org}.

Pharmacogenomic testing faces a related commercialization challenge: laboratory and physician adoption can advance ahead of payer consensus. Broader incorporation of actionable drug-gene relationships into coverage policy would improve ordering confidence and revenue visibility, whereas persistent policy variation keeps adoption concentrated in health systems and patient populations with established payment pathways ^{[4]Maryland Health Care Commission. “Senate Bill 961 — Pharmacogenomic Testing Report.” mhcc.maryland.gov}.

Workforce limitations are an additional constraint because ordering a complex test does not by itself ensure clinical utility. Genetic counselors, molecular pathologists, and clinical geneticists remain essential to interpretation and care navigation, making teleconsultation and governed automation important capacity multipliers in settings with limited specialist availability.

Genetic Testing Market Segment Analysis

By Products & Services

The Genetic Testing Market is supported by a products-and-services mix in which Kits & Reagents accounted for 57.0% of revenue in 2025 and are projected to generate USD 37.08 billion in 2035. Consumables retain a central role because every increase in testing throughput requires recurring assay inputs. Their position is reinforced by installed sequencing and PCR capacity, although a greater share of per-test value is expected to migrate to interpretation, workflow integration, and data management.

Software & Services are projected to represent 50.0% of market revenue in 2035 and to expand at a 14.0% CAGR (2026–2035). This trajectory reflects the commercial importance of bioinformatics, variant interpretation, laboratory information system integration, and clinical reporting. As panels become broader and repeat testing becomes more common, laboratories increasingly require software and professional services to turn raw genomic output into an actionable result.

By Test Type

The Genetic Testing Market's Prenatal & Newborn Testing segment generated USD 5.56 billion in 2025 and is projected to account for 21.0% of revenue in 2035. Its scale reflects established screening pathways and recurrent demand through obstetric care. Growth will increasingly depend on the breadth of covered screening indications and the ability of providers to integrate counseling and follow-up services into routine maternal care.

Diagnostic Testing is projected to generate USD 13.34 billion in 2035 and grow at an 11.7% CAGR (2026–2035). The segment benefits from a broad clinical base spanning inherited disease diagnosis, hereditary cancer assessment, and tumor profiling. Its resilience comes from the diversity of clinical questions addressed, although test utilization remains sensitive to clinician access to specialist interpretation and reimbursement clarity.

Predictive Testing accounted for 18.0% of revenue in 2025 and is expected to generate USD 14.83 billion in 2035. The category is supported by rising interest in proactive risk stratification, including hereditary cancer and cardiovascular risk assessment. Its adoption path is less standardized than diagnostic testing because ordering patterns depend on population-screening policy, care-provider confidence, and payer recognition of preventive value.

Pharmacogenomic Testing is projected to hold 18.0% of global revenue in 2035 and expand at a 15.2% CAGR (2026–2035). Demand is being shaped by a growing focus on medication selection and dosing in psychiatry, oncology, pain management, and cardiovascular care. The segment's upside is significant, but realization depends on broader payer recognition of clinical utility and on practical integration into prescribing workflows.

Carrier Testing is projected to generate USD 7.41 billion in 2035 and advance at an 11.3% CAGR (2026–2035). Expanded panels are broadening carrier assessment beyond legacy single-condition approaches. Demand is strongest where reproductive care providers can offer testing early enough for results to inform patient choices and where counseling capacity supports informed interpretation.

Nutrigenomics represented 7.0% of global revenue in 2025 and is projected to generate USD 5.19 billion in 2035. This category draws on consumer interest in personalized health and wellness but remains more commercially variable than clinically embedded testing segments. Its performance will depend on whether providers and consumers view diet-gene insights as sufficiently actionable to sustain repeat engagement.

By Application

The Genetic Testing Market's Cancer Treatment application generated USD 8.58 billion in 2025 and is projected to reach USD 29.66 billion in 2035. Oncology concentrates high-value demand because genetic results increasingly influence treatment selection, monitoring, and clinical trial eligibility. The transition from one-time tissue profiling to longitudinal liquid biopsy and residual disease monitoring can raise testing frequency within a patient's care journey.

Ancestry Testing is projected to account for 12.0% of global revenue in 2035 and grow at a 9.8% CAGR (2026–2035). The application is maturing in early-adopter consumer markets. Future expansion is more dependent on geographic penetration, consumer trust, and the ability of platforms to sustain engagement beyond an initial purchase.

Forensic Identity Testing accounted for 12.0% of revenue in 2025 and is projected to generate USD 8.89 billion in 2035. Government procurement, law-enforcement databases, and forensic genealogy applications create a demand base with different purchasing dynamics from clinical testing. Long procurement cycles and regulatory controls can moderate near-term variability while creating durable institutional requirements.

Tissue Typing for Transplantation is projected to generate USD 6.67 billion in 2035 and advance at a 13.6% CAGR (2026–2035). Demand is closely linked to transplant volumes and the clinical need for precise donor-recipient matching. Higher-resolution approaches can improve matching confidence and strengthen the role of genetic testing in both organ and hematopoietic transplant workflows.

Paternity Testing accounted for 5.0% of global revenue in 2025 and is projected to generate USD 3.70 billion in 2035. Legal, immigration, and family-law processes provide an institutional base for this application, supplemented by consumer-access channels. Demand tends to be steadier than for discretionary consumer genetics because a meaningful share of testing is linked to formal documentation requirements.

By Techniques

The Genetic Testing Market's NGS segment generated USD 8.35 billion in 2025 and is projected to reach USD 31.88 billion in 2035. NGS is increasingly used where broad variant detection, panel breadth, or high information density creates a material clinical advantage. Its growth is supported by oncology, rare disease, prenatal, and pharmacogenomic applications, although adoption requires investment in instruments, informatics, and skilled interpretation.

PCR is projected to account for 22.0% of global revenue in 2035 and expand at an 11.8% CAGR (2026–2035). PCR remains commercially important because it is familiar, cost-efficient, and compatible with a large installed laboratory base. It is particularly well suited to targeted workflows where rapid, validated answers are needed without the complexity of broad sequencing.

Microarrays accounted for 14.0% of revenue in 2025 and are expected to expand at an 8.6% CAGR (2026–2035). The technique retains a role in selected cytogenetic and constitutional testing pathways. Its growth is comparatively slower because broader sequencing approaches are gaining share in applications where higher resolution and wider variant detection are clinically valuable.

Sanger Sequencing represented 8.0% of global revenue in 2025 and is projected to generate USD 5.19 billion in 2035. Sanger sequencing remains relevant for confirmation and focused family-variant testing. Established validation practices and reimbursement familiarity support continued use, even as NGS becomes the preferred discovery method for many high-throughput settings.

Gene Expression Profiling is projected to generate USD 7.41 billion in 2035 and grow at a 13.5% CAGR (2026–2035). Transcriptomic information is gaining clinical relevance in oncology risk stratification and therapy selection. Expansion depends on continued validation of gene-expression signatures and their incorporation into decision pathways where clinicians can link results to a clear management action.

Chromosome Analysis is projected to account for 5.0% of global revenue in 2035 and advance at a 10.3% CAGR (2026–2035). Karyotyping remains clinically necessary where structural chromosomal changes require direct cytogenetic assessment. Rather than being replaced completely, it is likely to remain complementary to sequencing in prenatal and hematologic malignancy workflows.

FISH accounted for 4.0% of global revenue in 2025 and is expected to expand at a 9.1% CAGR (2026–2035). FISH continues to serve targeted, time-sensitive applications such as selected prenatal analyses and structural variant assessment. Its role is reinforced where a focused assay provides a clinically established answer more efficiently than a broader testing approach.

By End-Use

The Genetic Testing Market's Diagnostic Laboratories segment generated USD 9.74 billion in 2025 and is projected to reach USD 29.66 billion in 2035.

Reference and hospital-affiliated laboratories benefit from scale in test processing, informatics, reporting, and billing. Their ability to combine broad menus with established clinical relationships creates a durable advantage in complex testing categories. Hospitals & Clinics are projected to represent 38.0% of global revenue in 2035 and expand at a 13.6% CAGR (2026–2035).

Insourcing is strengthening this end-use segment as health systems seek faster turnaround for oncology and other time-sensitive decisions. The strategic value of retaining genomic data within the care delivery network also supports investment in internal laboratory capabilities.

Other End-Users accounted for 16.0% of revenue in 2025 and are projected to generate USD 11.86 billion in 2035. This group includes government programs, direct-to-consumer platforms, organ procurement organizations, and institutional testing settings with varied buying criteria. Its diversity helps broaden the market's demand base, but each subcategory faces distinct regulatory and commercial conditions.

Forensic Laboratories are projected to account for 6.0% of global revenue in 2035 and grow at a 9.1% CAGR (2026–2035). Public-sector procurement and long-standing DNA database programs create a relatively predictable demand environment. Growth depends on modernization of laboratory infrastructure, the scope of databank activity, and the incorporation of advanced forensic workflows into investigative practice.

Genetic Testing Market Regional Analysis

North America Genetic Testing Market Analysis

The Genetic Testing Market in North America generated USD 10.90 billion in 2025 and is projected to reach USD 29.82 billion in 2035. The region's scale reflects established laboratory networks, relatively advanced precision-oncology adoption, and a deep base of commercial and public reimbursement mechanisms. Its outlook remains tied to the pace at which coverage policy catches up with expanding clinical indications and to the capacity of providers to manage testing complexity.

U.S.

The U.S. generated USD 9.81 billion in 2025 and is projected to reach USD 26.83 billion in 2035. The U.S. market is anchored by oncology companion diagnostics, noninvasive prenatal testing, and a large reference-laboratory ecosystem. Federal coverage decisions, commercial benefit design, and state biomarker policies will remain influential in determining which clinically available tests reach broad patient populations.

Canada

Canada accounted for 10.0% of North American revenue in 2025 and is expected to expand at a 10.6% CAGR (2026–2035). Provincial reimbursement frameworks create differences in access across the country, while centralized laboratory networks and public research infrastructure support advanced testing capability. The market's trajectory is closely linked to provincial decisions on clinical implementation and covered indications.

Europe Genetic Testing Market Analysis

Europe is projected to account for 21.8% of global revenue in 2035 and grow at an 11.3% CAGR (2026–2035). National genomics programs, public health systems, and implementation of in vitro diagnostic regulation shape the region's testing environment. Market development varies by country because reimbursement, laboratory organization, and national sequencing infrastructure differ substantially across health systems.

UK

The UK generated USD 1.22 billion in 2025 and is projected to generate USD 3.56 billion in 2035. National genomic medicine infrastructure supports testing in rare disease and cancer pathways. The country's centralized approach can accelerate diffusion of validated services, though implementation remains dependent on laboratory capacity and integration with local clinical care.

Germany

Germany is projected to generate USD 3.07 billion in 2035 and accounted for 19.0% of European revenue in 2025. Its market combines statutory coverage for defined hereditary indications with private laboratory capacity and a substantial life sciences base. This structure supports demand across both clinical service delivery and testing-product supply chains.

France

France generated USD 780 million in 2025 and is projected to reach USD 2.26 billion in 2035. Publicly supported sequencing networks underpin demand in oncology and rare disease care. Continued growth depends on the ability of hospital-centered genomics infrastructure to expand routine clinical access beyond highly specialized referral pathways.

Italy

Italy is projected to generate USD 1.29 billion in 2035 and accounted for 8.0% of European revenue in 2025. University-affiliated hospitals remain important centers for complex genetic testing. Regional healthcare administration can produce uneven adoption, making local laboratory capability and reimbursement decisions important determinants of market access.

Spain

Spain generated USD 446 million in 2025 and is expected to grow at an 11.3% CAGR (2026–2035). Testing demand is supported by public coverage in defined prenatal and hereditary cancer settings. Broader expansion will depend on the pace at which national and regional health authorities translate guideline updates into funded testing pathways.

Netherlands

The Netherlands is projected to generate USD 971 million in 2035 and accounted for 6.0% of European revenue in 2025. A well-developed prenatal screening environment supports an established testing base. Its outlook also benefits from high institutional readiness to incorporate validated genomic services into organized care pathways.

Asia Pacific Genetic Testing Market Analysis

The Genetic Testing Market in Asia Pacific generated USD 4.87 billion in 2025 and is projected to reach USD 21.41 billion in 2035. Asia Pacific's expansion is supported by government genomics initiatives, growing clinical sequencing capacity, and a large addressable patient population. The region's ultimate realization will vary with payer development, specialist availability, domestic laboratory capacity, and the ability to build population-relevant genomic reference data.

China

China generated USD 1.70 billion in 2025 and is projected to reach USD 7.49 billion in 2035. Large-scale prenatal testing adoption and precision-medicine investment support demand across hospital and sequencing-service settings. Domestic suppliers and tertiary-hospital networks are central to the market's development, particularly in oncology and population genomics applications.

Japan

Japan is projected to account for 22.0% of Asia Pacific revenue in 2035 and expand at a 16.0% CAGR (2026–2035). National insurance coverage for selected genomic oncology applications provides an important clinical foundation. An aging population may also strengthen demand for testing that supports treatment optimization and proactive risk assessment.

India

India generated USD 779 million in 2025 and is projected to reach USD 3.42 billion in 2035. Population genomics activity, growing private hospital networks, and an expanding biotechnology ecosystem are improving the basis for clinical testing. Wider access will depend on affordability, locally appropriate reference data, and the diffusion of specialized laboratory and counseling capacity beyond major cities.

South Korea

South Korea is projected to account for 13.0% of Asia Pacific revenue in 2035 and generated USD 633 million in 2025. The country combines established clinical infrastructure with a sophisticated regulatory environment and strong domestic sequencing capabilities. These attributes support adoption in hereditary cancer, prenatal testing, and other clinically integrated applications.

Australia

Australia accounted for 10.0% of Asia Pacific revenue in 2025 and is projected to generate USD 2.14 billion in 2035. Publicly supported genomics programs and teaching-hospital infrastructure support testing in cancer and rare disease care. Continued expansion will depend on embedding research-backed genomic services into consistently funded clinical pathways.

Latin America Genetic Testing Market Analysis

Latin America is projected to account for 5.4% of global revenue in 2035 and grow at a 13.3% CAGR (2026–2035). The region is developing from a comparatively lower installed base, with demand concentrated in major urban laboratory networks and private healthcare channels. Expanding insurance coverage and investment in diagnostic infrastructure can improve access, particularly for oncology and pediatric rare disease testing.

Brazil

Brazil generated USD 638 million in 2025 and is projected to reach USD 2.21 billion in 2035. Brazil's private hospital and laboratory networks provide a foundation for advanced testing, while public-system adoption remains an important avenue for broader access. Major metropolitan areas are likely to remain the principal centers for high-complexity testing capacity.

Mexico

Mexico is projected to account for 30.0% of Latin American revenue in 2035 and grow at a 13.3% CAGR (2026–2035). Private laboratories and insurers are key commercial channels, especially in major urban areas. Rising awareness of hereditary cancer and greater availability of diagnostic services can support adoption, although access remains shaped by affordability and insurer benefit design.

Middle East & Africa Genetic Testing Market Analysis

Middle East & Africa generated USD 696 million in 2025 and is projected to grow at a 14.6% CAGR (2026–2035). Government healthcare investment in Gulf markets and gradual clinical-genetics capacity development elsewhere support the regional outlook. Demand for carrier screening and prenatal testing is particularly relevant in settings with a high burden of inherited disorders, while specialist workforce availability remains a practical limitation.

Saudi Arabia

Saudi Arabia accounted for 30.0% of Middle East & Africa revenue in 2025 and is projected to generate USD 813 million in 2035. Healthcare transformation and national investment in precision medicine are strengthening the country's diagnostic genomics infrastructure. Newborn screening and carrier-screening programs can provide a structured route to broader testing utilization.

UAE

The UAE is projected to generate USD 759 million in 2035 and accounted for 28.0% of Middle East & Africa revenue in 2025. A strong private healthcare environment and government-backed genomics initiatives support premium diagnostic service demand. The country's role as a regional healthcare hub can also strengthen its position in specialized laboratory and referral activity.

South Africa

South Africa generated USD 125 million in 2025 and is expected to expand at a 14.6% CAGR (2026–2035). Private healthcare and academic hospital networks underpin the current market, particularly in hereditary cancer and cytogenetic testing. Broader development depends on improving specialist availability and extending access beyond insured urban populations.

Genetic Testing Market Share & Competitive Landscape

The Genetic Testing Market share structure is moderately concentrated, with the top five participants collectively accounting for approximately 27.1% of global revenue in 2025. Competition is shaped by differences in assay specialization, laboratory reach, sequencing-platform exposure, reimbursement expertise, clinical evidence generation, and the ability to integrate testing into provider workflows.

Natera, Inc.

Natera held a 10.0% global market share in 2025. Its position is anchored in cell-free DNA testing across prenatal screening, oncology monitoring, and organ-health surveillance, with molecular residual disease representing an increasingly important commercial pathway.

The company's strategic position depends on deepening evidence and payer support for longitudinal oncology testing. Its ability to connect assay performance with coverage expansion gives it a differentiated position in clinical workflows where testing can recur through treatment and surveillance.

Illumina, Inc.

Illumina held a 7.5% share of the global genetic testing market in 2025. Its exposure differs from testing service providers because its platforms, reagents, and software are embedded within laboratory workflows that support clinical NGS.

The company's competitive importance rests on the breadth of its installed base and its ability to support clinical genomics adoption across laboratory tiers. Its appointment of Eric Green as Chief Medical Officer reflects a strategic focus on clinical genomics engagement and precision-medicine infrastructure ^{[6]Illumina, Inc. “Illumina Appoints Dr. Eric Green as Chief Medical Officer.” illumina.com}.

Quest Diagnostics

Quest Diagnostics held a 3.3% global market share in 2025. Its broad laboratory network and clinician access provide a distribution advantage for genetic and molecular diagnostic services.

Its competitive role is reinforced by scale in specimen logistics, laboratory operations, reporting, and reimbursement administration. Partnerships and menu expansion can allow the company to broaden access to emerging assays without requiring every test to be developed internally.

QIAGEN N.V.

QIAGEN participates through sample technologies, companion diagnostics, and molecular testing platforms used by institutional laboratories. Its relevance to genetic testing is strongest where workflow reliability, assay preparation, and integration with oncology biomarker testing influence laboratory purchasing decisions.

The company's positioning benefits from serving both research-to-clinical translation and established diagnostic laboratory workflows. Its acquisition of Parse Biosciences expands its exposure to single-cell transcriptomics and related translational applications.

Myriad Genetics, Inc.

Myriad Genetics maintains a strong presence in hereditary cancer testing and oncology risk assessment. Its commercial strategy emphasizes a broader cancer-care continuum that can connect inherited-risk testing with treatment selection and molecular monitoring.

The company's future differentiation will depend on translating its established clinical relationships into newer liquid-biopsy and companion-diagnostic opportunities. Its collaboration with SOPHiA GENETICS reflects an effort to combine laboratory and regulatory capabilities with international deployment infrastructure ^{[7]Myriad Genetics, Inc. “Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy.” investor.myriad.com}.

23andMe, Inc.

23andMe remains a significant consumer-facing participant in ancestry and health genetics. Its strategic challenge is to develop enduring value beyond an initial consumer test purchase while addressing trust, data governance, and the commercial limits of mature direct-to-consumer channels.

Abbott Laboratories

Abbott participates through molecular diagnostic instruments and PCR-based systems used by hospital and reference laboratories. Its installed laboratory footprint gives it a route to support genetic test-menu expansion where customers prioritize operational familiarity and integrated diagnostics infrastructure.

Ambry Genetics

Ambry Genetics is positioned in specialty clinical genetics, including hereditary cancer, cardiogenetics, and rare disease. Its competitive relevance derives from multigene panel capability and variant interpretation expertise, which remain important barriers in complex hereditary testing.

Ancestry DNA

Ancestry DNA competes primarily in consumer ancestry and genealogy testing. Its large consumer database and reference-population capabilities differentiate it within a segment where user engagement, privacy expectations, and perceived utility shape commercial performance.

bioMerieux SA

bioMerieux serves clinical laboratories through molecular and syndromic testing platforms. Its position is supported by hospital and public-health laboratory relationships, particularly where molecular testing must fit into broader diagnostic workflows.

BGI Genomics

BGI Genomics operates large-scale sequencing capacity and has a substantial presence in China and international sequencing services. Its scale supports both clinical testing and population genomics activity, giving it exposure to markets where national genomic programs are expanding.

Invitae Corporation

Invitae has focused on inherited-condition testing across hereditary cancer, cardiology, neurology, and rare disease. Its panel-based approach reflects the industry's movement away from sequential single-gene testing toward broader diagnostic workups.

Luminex Corporation

Luminex, operating within the DiaSorin Group, provides multiplex technology used in clinical laboratory testing and biomarker analysis. Its platforms remain relevant to HLA typing, pharmacogenomic applications, and multiplexed molecular workflows.

Siemens Healthineers AG

Siemens Healthineers participates through laboratory diagnostics, automation, and molecular health solutions. Its customer relationships with hospitals and independent laboratories position it to support operational integration as genetic testing becomes more embedded in mainstream diagnostic services.

Recent Industry Developments

Natera completed its acquisition of Foresight Diagnostics in December 2025, adding PhasED-Seq technology intended to strengthen molecular residual disease detection capabilities and extend the company's oncology monitoring portfolio into hematologic malignancies ^{[5]Natera, Inc. “Natera Acquires Foresight Diagnostics.” natera.com}.

Illumina appointed Eric D. Green, M.D., Ph.D., as Chief Medical Officer, effective February 2026. The appointment aligns with the company's emphasis on clinical genomics adoption, access to precision medicine, and global genomic-data diversity ^{[6]Illumina, Inc. “Illumina Appoints Dr. Eric Green as Chief Medical Officer.” illumina.com}.

Myriad Genetics and SOPHiA GENETICS announced a global collaboration in September 2025 to develop and commercialize a liquid-biopsy companion diagnostic offering for pharmaceutical clients ^{[7]Myriad Genetics, Inc. “Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy.” investor.myriad.com}.